First evaluation of QuantiFERON-TB Gold Plus performance in contact screening
Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of interferon-γ release assay, QuantiFERON-TB Plus (QFT-Plus), which includes an additional antigen tube (TB2), stimulating both CD4 + and CD8...
Saved in:
Published in | The European respiratory journal Vol. 48; no. 5; pp. 1411 - 1419 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.11.2016
|
Subjects | |
Online Access | Get full text |
ISSN | 0903-1936 1399-3003 |
DOI | 10.1183/13993003.00510-2016 |
Cover
Loading…
Abstract | Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of interferon-γ release assay, QuantiFERON-TB Plus (QFT-Plus), which includes an additional antigen tube (TB2), stimulating both CD4 + and CD8 + T-cells in contacts of TB patients.
Contacts were screened for latent TB infection by tuberculin skin test, QFT-Plus and QuantiFERON-TB Gold in Tube (QFT-GIT).
In 119 TB contacts, the overall agreement between QFT-Plus and QFT-GIT was high, with a Cohen's κ of 0.8. Discordant results were found in 12 subjects with negative QFT-GIT and positive QFT-Plus results. In analyses of markers of TB exposure and test results, the average time spent with the index case was the strongest risk factor for positivity in each of these tests. The difference in interferon-γ production between the two antigen tubes (TB2−TB1) was used as an estimate of CD8 + stimulation provided by the TB2. TB2−TB1 values >0.6 IU·mL −1 were significantly associated with proximity to the index case and European origin.
QFT-Plus has a stronger association with surrogate measures of TB exposure than QFT-GIT in adults screened for latent TB infection. Interferon-γ response in the new antigen tube used an indirect estimate of specific CD8 + response correlates with increased Mycobacterium tuberculosis exposure, suggesting a possible role in identifying individuals with recent infection. |
---|---|
AbstractList | Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of interferon-γ release assay, QuantiFERON-TB Plus (QFT-Plus), which includes an additional antigen tube (TB2), stimulating both CD4+ and CD8+ T-cells in contacts of TB patients.Contacts were screened for latent TB infection by tuberculin skin test, QFT-Plus and QuantiFERON-TB Gold in Tube (QFT-GIT).In 119 TB contacts, the overall agreement between QFT-Plus and QFT-GIT was high, with a Cohen's κ of 0.8. Discordant results were found in 12 subjects with negative QFT-GIT and positive QFT-Plus results. In analyses of markers of TB exposure and test results, the average time spent with the index case was the strongest risk factor for positivity in each of these tests. The difference in interferon-γ production between the two antigen tubes (TB2-TB1) was used as an estimate of CD8+ stimulation provided by the TB2. TB2-TB1 values >0.6 IU·mL-1 were significantly associated with proximity to the index case and European origin.QFT-Plus has a stronger association with surrogate measures of TB exposure than QFT-GIT in adults screened for latent TB infection. Interferon-γ response in the new antigen tube used an indirect estimate of specific CD8+ response correlates with increased Mycobacterium tuberculosis exposure, suggesting a possible role in identifying individuals with recent infection. Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of interferon-γ release assay, QuantiFERON-TB Plus (QFT-Plus), which includes an additional antigen tube (TB2), stimulating both CD4 + and CD8 + T-cells in contacts of TB patients. Contacts were screened for latent TB infection by tuberculin skin test, QFT-Plus and QuantiFERON-TB Gold in Tube (QFT-GIT). In 119 TB contacts, the overall agreement between QFT-Plus and QFT-GIT was high, with a Cohen's κ of 0.8. Discordant results were found in 12 subjects with negative QFT-GIT and positive QFT-Plus results. In analyses of markers of TB exposure and test results, the average time spent with the index case was the strongest risk factor for positivity in each of these tests. The difference in interferon-γ production between the two antigen tubes (TB2−TB1) was used as an estimate of CD8 + stimulation provided by the TB2. TB2−TB1 values >0.6 IU·mL −1 were significantly associated with proximity to the index case and European origin. QFT-Plus has a stronger association with surrogate measures of TB exposure than QFT-GIT in adults screened for latent TB infection. Interferon-γ response in the new antigen tube used an indirect estimate of specific CD8 + response correlates with increased Mycobacterium tuberculosis exposure, suggesting a possible role in identifying individuals with recent infection. Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of interferon-γ release assay, QuantiFERON-TB Plus (QFT-Plus), which includes an additional antigen tube (TB2), stimulating both CD4 and CD8 T-cells in contacts of TB patients.Contacts were screened for latent TB infection by tuberculin skin test, QFT-Plus and QuantiFERON-TB Gold in Tube (QFT-GIT).In 119 TB contacts, the overall agreement between QFT-Plus and QFT-GIT was high, with a Cohen's κ of 0.8. Discordant results were found in 12 subjects with negative QFT-GIT and positive QFT-Plus results. In analyses of markers of TB exposure and test results, the average time spent with the index case was the strongest risk factor for positivity in each of these tests. The difference in interferon-γ production between the two antigen tubes (TB2-TB1) was used as an estimate of CD8 stimulation provided by the TB2. TB2-TB1 values >0.6 IU·mL were significantly associated with proximity to the index case and European origin.QFT-Plus has a stronger association with surrogate measures of TB exposure than QFT-GIT in adults screened for latent TB infection. Interferon-γ response in the new antigen tube used an indirect estimate of specific CD8 response correlates with increased Mycobacterium tuberculosis exposure, suggesting a possible role in identifying individuals with recent infection. |
Author | Brown, James Cugnata, Federica Ferrarese, Maurizio Russo, Giulia Borroni, Emanuele Brunetti, Enrico Castellotti, Paola F. Lipman, Marc Cirillo, Daniela M. Codecasa, Luigi R. Campisi, Daniela Barcellini, Lucia Goletti, Delia Di Serio, Clelia Vanino, Elisa Tadolini, Marina Rancoita, Paola M.V. |
Author_xml | – sequence: 1 givenname: Lucia surname: Barcellini fullname: Barcellini, Lucia – sequence: 2 givenname: Emanuele surname: Borroni fullname: Borroni, Emanuele – sequence: 3 givenname: James surname: Brown fullname: Brown, James – sequence: 4 givenname: Enrico surname: Brunetti fullname: Brunetti, Enrico – sequence: 5 givenname: Daniela surname: Campisi fullname: Campisi, Daniela – sequence: 6 givenname: Paola F. surname: Castellotti fullname: Castellotti, Paola F. – sequence: 7 givenname: Luigi R. surname: Codecasa fullname: Codecasa, Luigi R. – sequence: 8 givenname: Federica surname: Cugnata fullname: Cugnata, Federica – sequence: 9 givenname: Clelia surname: Di Serio fullname: Di Serio, Clelia – sequence: 10 givenname: Maurizio surname: Ferrarese fullname: Ferrarese, Maurizio – sequence: 11 givenname: Delia surname: Goletti fullname: Goletti, Delia – sequence: 12 givenname: Marc surname: Lipman fullname: Lipman, Marc – sequence: 13 givenname: Paola M.V. surname: Rancoita fullname: Rancoita, Paola M.V. – sequence: 14 givenname: Giulia surname: Russo fullname: Russo, Giulia – sequence: 15 givenname: Marina surname: Tadolini fullname: Tadolini, Marina – sequence: 16 givenname: Elisa surname: Vanino fullname: Vanino, Elisa – sequence: 17 givenname: Daniela M. surname: Cirillo fullname: Cirillo, Daniela M. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27390280$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kEtLxDAUhYMoOj5-gSBZuqnmNn1lqTIzCuqojOuQprcS6SRjkgr-e9vR2bhwdeHwncPlOyS71lkk5BTYBUDFL4ELwRnjF4zlwJKUQbFDJmOajPEumTDBeAKCFwfkMIR3NhAZh31ykJZcsLRiE_IwMz5Eip-q61U0zlLX0ude2Whm05fFY7K8pnPXNfSp6wNdo2-dXymrkRpLtbNR6UiD9ojW2LdjsteqLuDJ7z0ir7Pp8uY2uV_M726u7hOdQRGTcnisLlXKy0ZA1gJrspJpgVCUArFtKqZrBF5kdd3WKs9UlQuOIq0Ri6ZqNT8i5z-7a-8-egxRrkzQ2HXKouuDhCotShA5pAN69ov29QobufZmpfyX3CoYAPEDaO9C8NhKbeJGRfTKdBKYHHXLrW650S1H3UOX_-lu5_9rfQM9doBr |
CitedBy_id | crossref_primary_10_3389_fimmu_2024_1383098 crossref_primary_10_1183_20734735_0079_2021 crossref_primary_10_1513_AnnalsATS_201905_407RL crossref_primary_10_1016_S1877_1203_19_30134_X crossref_primary_10_1097_INF_0000000000002711 crossref_primary_10_14745_ccdr_v43i34a01 crossref_primary_10_1371_journal_pgph_0002077 crossref_primary_10_1371_journal_pone_0213304 crossref_primary_10_1128_spectrum_02445_21 crossref_primary_10_1007_s00296_023_05320_7 crossref_primary_10_1183_13993003_01267_2017 crossref_primary_10_1136_thorax_2022_218929 crossref_primary_10_1016_j_jinf_2017_07_004 crossref_primary_10_1007_s00430_018_00576_4 crossref_primary_10_1080_23744235_2017_1279747 crossref_primary_10_47429_lmo_2023_13_2_85 crossref_primary_10_1183_13993003_02563_2021 crossref_primary_10_1016_j_clinmicnews_2018_08_005 crossref_primary_10_7759_cureus_35706 crossref_primary_10_1016_j_tube_2017_11_014 crossref_primary_10_1155_2017_8909834 crossref_primary_10_3904_kjim_2019_002 crossref_primary_10_12688_gatesopenres_13191_2 crossref_primary_10_12688_gatesopenres_13191_3 crossref_primary_10_1183_13993003_01578_2017 crossref_primary_10_12688_gatesopenres_13191_1 crossref_primary_10_1016_j_tube_2017_06_002 crossref_primary_10_1128_Spectrum_00972_21 crossref_primary_10_1080_21505594_2021_1990660 crossref_primary_10_1016_j_jiac_2017_09_012 crossref_primary_10_1016_j_tube_2017_07_011 crossref_primary_10_1111_resp_13106 crossref_primary_10_1016_j_arbres_2020_04_011 crossref_primary_10_1016_j_jinf_2019_01_008 crossref_primary_10_1371_journal_pone_0193589 crossref_primary_10_1016_j_jinf_2019_01_007 crossref_primary_10_1016_j_lpm_2017_01_015 crossref_primary_10_3389_fimmu_2020_02006 crossref_primary_10_1016_j_ijid_2019_11_023 crossref_primary_10_1016_j_rppnen_2017_10_007 crossref_primary_10_1111_1744_9987_13939 crossref_primary_10_1016_j_rmed_2021_106508 crossref_primary_10_1371_journal_pgph_0003182 crossref_primary_10_1016_j_jctube_2024_100504 crossref_primary_10_1093_rheumatology_kez390 crossref_primary_10_3343_alm_2020_40_1_33 crossref_primary_10_1183_13993003_00896_2019 crossref_primary_10_1038_s41598_018_33825_w crossref_primary_10_1097_MOP_0000000000000581 crossref_primary_10_1128_JCM_01360_17 crossref_primary_10_1016_j_rmr_2018_08_010 crossref_primary_10_1016_j_advms_2019_09_001 crossref_primary_10_1183_13993003_01089_2018 crossref_primary_10_1016_j_jiac_2021_08_016 crossref_primary_10_1016_j_jinf_2019_08_018 crossref_primary_10_1016_j_jinf_2020_02_009 crossref_primary_10_1136_thoraxjnl_2017_211147 crossref_primary_10_1183_13993003_04078_2020 crossref_primary_10_1183_23120541_00511_2021 crossref_primary_10_1080_23744235_2024_2313668 crossref_primary_10_1183_13993003_01630_2017 crossref_primary_10_58395_pipd_v47i1_15 crossref_primary_10_1093_clinchem_hvad220 crossref_primary_10_1128_JCM_00272_20 crossref_primary_10_1016_j_jmii_2023_07_014 crossref_primary_10_1016_j_jinf_2020_02_007 crossref_primary_10_1016_j_jiac_2020_06_019 crossref_primary_10_4236_jtr_2024_124013 crossref_primary_10_1016_j_jiac_2021_08_003 crossref_primary_10_1080_07853890_2020_1800073 crossref_primary_10_1097_INF_0000000000003173 crossref_primary_10_1016_j_jinf_2019_04_010 crossref_primary_10_1016_j_jiac_2020_01_011 crossref_primary_10_1183_13993003_01012_2016 crossref_primary_10_1016_j_arbres_2020_04_026 crossref_primary_10_1128_JCM_00985_19 crossref_primary_10_1016_j_pulmoe_2021_07_003 crossref_primary_10_1016_j_ebiom_2024_105196 crossref_primary_10_1128_JCM_00438_18 crossref_primary_10_1016_j_tube_2020_101966 crossref_primary_10_1016_j_ijid_2022_02_047 crossref_primary_10_1183_13993003_00391_2019 crossref_primary_10_1371_journal_pone_0234700 crossref_primary_10_1080_14737159_2017_1308825 crossref_primary_10_5144_0256_4947_2020_191 crossref_primary_10_3889_oamjms_2021_6859 crossref_primary_10_3389_fimmu_2021_619988 crossref_primary_10_4103_ijmy_ijmy_44_21 crossref_primary_10_1097_JOM_0000000000001904 crossref_primary_10_24293_ijcpml_v30i3_2212 crossref_primary_10_3390_ijerph14030236 crossref_primary_10_4103_ijmy_ijmy_112_22 crossref_primary_10_1128_JCM_01370_21 crossref_primary_10_1515_cclm_2023_0293 crossref_primary_10_1016_j_tube_2020_101959 crossref_primary_10_1128_JCM_01950_19 crossref_primary_10_1016_j_ccm_2019_07_002 crossref_primary_10_1186_s12879_023_08008_2 crossref_primary_10_1371_journal_pone_0187313 crossref_primary_10_1016_j_jctube_2019_100102 crossref_primary_10_1016_j_ccm_2019_07_007 crossref_primary_10_1016_j_jinf_2019_07_007 crossref_primary_10_1093_cid_ciad030 crossref_primary_10_1016_j_arbr_2021_06_002 crossref_primary_10_1007_s10067_021_05663_1 crossref_primary_10_1093_cid_ciaa1822 crossref_primary_10_1016_j_cca_2023_117559 crossref_primary_10_1038_s41598_020_78374_3 crossref_primary_10_1183_23120541_00258_2018 crossref_primary_10_2174_0118715265275319231124053615 crossref_primary_10_1128_JCM_00614_18 |
Cites_doi | 10.1002/eji.201243262 10.4049/jimmunol.0801694 10.1183/09031936.00205512 10.1016/S0140-6736(00)02742-2 10.1056/NEJMra1405427 10.4049/jimmunol.1101122 10.1183/09031936.00089510 10.1016/S1473-3099(07)70086-5 10.1016/S0140-6736(15)01316-1 10.1164/rccm.201203-0430OC 10.1371/journal.pone.0018315 10.1164/rccm.200306-837OC 10.1016/S1473-3099(11)70210-9 10.1017/S095026881400394X 10.1086/382362 10.5588/ijtld.10.0631 10.1016/j.diagmicrobio.2012.11.023 10.1164/rccm.201107-1355OC 10.1016/j.jinf.2014.06.009 10.1164/ajrccm.149.5.8173779 10.1001/jama.282.7.677 10.1371/journal.pone.0043285 10.1183/13993003.00263-2015 10.1183/09031936.00114810 10.1183/13993003.02033-2015 10.1017/S0950268897007917 10.1371/journal.pone.0096564 10.1164/rccm.201412-2141OC 10.1016/j.jinf.2015.07.009 10.1183/09031936.00214014 10.1371/journal.pone.0032482 10.1016/j.ebiom.2015.01.009 |
ContentType | Journal Article |
Copyright | Copyright ©ERS 2016. |
Copyright_xml | – notice: Copyright ©ERS 2016. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1183/13993003.00510-2016 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1399-3003 |
EndPage | 1419 |
ExternalDocumentID | 27390280 10_1183_13993003_00510_2016 |
Genre | Journal Article |
GroupedDBID | --- .55 .GJ 18M 1OC 2WC 31~ 3O- 53G 5GY 5RE 5VS 8-1 AADJU AAFWJ AAYXX AAZMJ ABCQX ABJNI ABOCM ABSQV ACEMG ACGFO ACPRK ACXQS ADBBV ADDZX ADMOG ADYFA AENEX AFFNX AFHIN AFZJQ AIZTS AJAOE ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CAG CITATION COF CS3 DIK E3Z EBS EJD F5P F9R GX1 H13 INIJC J5H KQ8 L7B LH4 LW6 OK1 P2P PQQKQ R0Z RHI TER TR2 W8F WOQ X7M ZE2 ZGI ZXP ~02 CGR CUY CVF ECM EIF NPM RHF 7X8 |
ID | FETCH-LOGICAL-c416t-7090b7a237d914f10d470c9e1679eefd80cbe1364bbfba54a8593e92bee6d8fc3 |
ISSN | 0903-1936 |
IngestDate | Thu Jul 10 18:35:58 EDT 2025 Wed Feb 19 02:42:34 EST 2025 Sun Jul 06 05:02:55 EDT 2025 Thu Apr 24 23:04:41 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
License | Copyright ©ERS 2016. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c416t-7090b7a237d914f10d470c9e1679eefd80cbe1364bbfba54a8593e92bee6d8fc3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://erj.ersjournals.com/content/erj/48/5/1411.full.pdf |
PMID | 27390280 |
PQID | 1826719512 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_1826719512 pubmed_primary_27390280 crossref_citationtrail_10_1183_13993003_00510_2016 crossref_primary_10_1183_13993003_00510_2016 |
PublicationCentury | 2000 |
PublicationDate | 2016-11-01 |
PublicationDateYYYYMMDD | 2016-11-01 |
PublicationDate_xml | – month: 11 year: 2016 text: 2016-11-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | The European respiratory journal |
PublicationTitleAlternate | Eur Respir J |
PublicationYear | 2016 |
References | 2024102100071623000_48.5.1411.29 2024102100071623000_48.5.1411.28 2024102100071623000_48.5.1411.25 2024102100071623000_48.5.1411.24 2024102100071623000_48.5.1411.27 2024102100071623000_48.5.1411.26 2024102100071623000_48.5.1411.21 Farhat (2024102100071623000_48.5.1411.7) 2006; 10 2024102100071623000_48.5.1411.20 2024102100071623000_48.5.1411.23 Rangaka (2024102100071623000_48.5.1411.12) 2015; 12 2024102100071623000_48.5.1411.22 2024102100071623000_48.5.1411.30 2024102100071623000_48.5.1411.1 2024102100071623000_48.5.1411.18 2024102100071623000_48.5.1411.17 2024102100071623000_48.5.1411.19 2024102100071623000_48.5.1411.14 2024102100071623000_48.5.1411.36 2024102100071623000_48.5.1411.13 2024102100071623000_48.5.1411.35 2024102100071623000_48.5.1411.16 2024102100071623000_48.5.1411.15 2024102100071623000_48.5.1411.10 2024102100071623000_48.5.1411.32 2024102100071623000_48.5.1411.31 2024102100071623000_48.5.1411.34 2024102100071623000_48.5.1411.11 2024102100071623000_48.5.1411.33 2024102100071623000_48.5.1411.8 2024102100071623000_48.5.1411.9 2024102100071623000_48.5.1411.6 2024102100071623000_48.5.1411.4 2024102100071623000_48.5.1411.5 2024102100071623000_48.5.1411.2 2024102100071623000_48.5.1411.3 |
References_xml | – ident: 2024102100071623000_48.5.1411.23 doi: 10.1002/eji.201243262 – ident: 2024102100071623000_48.5.1411.25 doi: 10.4049/jimmunol.0801694 – ident: 2024102100071623000_48.5.1411.3 doi: 10.1183/09031936.00205512 – ident: 2024102100071623000_48.5.1411.8 doi: 10.1016/S0140-6736(00)02742-2 – ident: 2024102100071623000_48.5.1411.1 doi: 10.1056/NEJMra1405427 – ident: 2024102100071623000_48.5.1411.22 doi: 10.4049/jimmunol.1101122 – ident: 2024102100071623000_48.5.1411.32 doi: 10.1183/09031936.00089510 – ident: 2024102100071623000_48.5.1411.33 doi: 10.1016/S1473-3099(07)70086-5 – ident: 2024102100071623000_48.5.1411.18 doi: 10.1016/S0140-6736(15)01316-1 – ident: 2024102100071623000_48.5.1411.30 doi: 10.1164/rccm.201203-0430OC – ident: 2024102100071623000_48.5.1411.14 doi: 10.1371/journal.pone.0018315 – ident: 2024102100071623000_48.5.1411.21 doi: 10.1164/rccm.200306-837OC – ident: 2024102100071623000_48.5.1411.29 – ident: 2024102100071623000_48.5.1411.27 – volume: 12 start-page: 45 year: 2015 ident: 2024102100071623000_48.5.1411.12 article-title: Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(11)70210-9 – ident: 2024102100071623000_48.5.1411.26 doi: 10.1017/S095026881400394X – ident: 2024102100071623000_48.5.1411.28 doi: 10.1086/382362 – ident: 2024102100071623000_48.5.1411.11 doi: 10.5588/ijtld.10.0631 – ident: 2024102100071623000_48.5.1411.24 doi: 10.1016/j.diagmicrobio.2012.11.023 – ident: 2024102100071623000_48.5.1411.35 doi: 10.1164/rccm.201107-1355OC – ident: 2024102100071623000_48.5.1411.34 doi: 10.1016/j.jinf.2014.06.009 – ident: 2024102100071623000_48.5.1411.6 doi: 10.1164/ajrccm.149.5.8173779 – ident: 2024102100071623000_48.5.1411.4 doi: 10.1001/jama.282.7.677 – ident: 2024102100071623000_48.5.1411.13 doi: 10.1371/journal.pone.0043285 – ident: 2024102100071623000_48.5.1411.19 doi: 10.1183/13993003.00263-2015 – ident: 2024102100071623000_48.5.1411.9 doi: 10.1183/09031936.00114810 – ident: 2024102100071623000_48.5.1411.36 doi: 10.1183/13993003.02033-2015 – ident: 2024102100071623000_48.5.1411.5 doi: 10.1017/S0950268897007917 – ident: 2024102100071623000_48.5.1411.31 doi: 10.1371/journal.pone.0096564 – ident: 2024102100071623000_48.5.1411.15 doi: 10.1164/rccm.201412-2141OC – ident: 2024102100071623000_48.5.1411.16 doi: 10.1016/j.jinf.2015.07.009 – ident: 2024102100071623000_48.5.1411.2 doi: 10.1183/09031936.00214014 – volume: 10 start-page: 1192 year: 2006 ident: 2024102100071623000_48.5.1411.7 article-title: False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? publication-title: Int J Tuberc Lung Dis – ident: 2024102100071623000_48.5.1411.10 doi: 10.1371/journal.pone.0032482 – ident: 2024102100071623000_48.5.1411.20 – ident: 2024102100071623000_48.5.1411.17 doi: 10.1016/j.ebiom.2015.01.009 |
SSID | ssj0016431 |
Score | 2.548529 |
Snippet | Identifying latently infected individuals is crucial for the elimination of tuberculosis (TB). We evaluated for the first time the performance of a new type of... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 1411 |
SubjectTerms | Adult Aged CD4-Positive T-Lymphocytes - cytology CD8-Positive T-Lymphocytes - cytology Contact Tracing - methods Cross-Sectional Studies Female Humans Incidence Interferon-gamma Interferon-gamma Release Tests - methods Italy Latent Tuberculosis - diagnosis Latent Tuberculosis - transmission Male Middle Aged Models, Statistical Mycobacterium tuberculosis Tuberculin Test - methods Tuberculosis, Pulmonary - diagnosis |
Title | First evaluation of QuantiFERON-TB Gold Plus performance in contact screening |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27390280 https://www.proquest.com/docview/1826719512 |
Volume | 48 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWIiEuqDy7tCAjcSspTuK8jgV2KaBFgLZSb1EcO1LQ4lTb5NJf3xnHSVzRIuASrRzvOJr5NJ7xPEzIax5LKaO48MoiyTwOm4gnWCq8GOZjnEwVGRYnr77GJ6f881l0NptVTtZS14qj8vLGupL_kSqMgVyxSvYfJDsShQH4DfKFJ0gYnn8l42UNtpvTsBstv-8d8KpeLn6Ajly_O_zYbOTht013gQ2KxxIBk3yuW6yPBLUBruywgf2cwDOe02-daLz7Web805z817qvse7KevLvmy223TW6Fhbt1MaJ31vX36ToTqOdVm2fXbDQoJ4b90TCj21pntlQei0KVo8XMha6apanDpwiR2f6vFe3vyvzFJtKIDGkdWT0h4cLurNBIue_jHzBEDOtaKadbcw3HF7dIXcDcCfwposPn76M0SawynzbkQrWfHvDitgz2tK4bsDc4pUY62S9Sx5Yt4Ie9xh5SGZKPyL3VjZx4jFZGajQCSq0qeh1qFCECkWoUAcqtNbUQoWOUHlCTpeL9fsTz96k4ZVgcLdewjImkiIIE5n5vPKZ5AkrM4UxOKUqmbJSKD-MuRCVKCJeYBc8lQVCqVimVRk-JTu60WqP0FgCqYoBjYJzFkiRJoUIS8VkpdKoSuYkGNiTl7bNPN52ssmNu5mG-cDe3LA3R_bOyZvxT-d9l5U_T3818D0HbYhAL7RquoscveXEB68hmJNnvUBGgoMAn9_6Zp_cn_B8QHbabadegM3ZipcGMFfNuH0I |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=First+evaluation+of+QuantiFERON-TB+Gold+Plus+performance+in+contact+screening&rft.jtitle=The+European+respiratory+journal&rft.au=Barcellini%2C+Lucia&rft.au=Borroni%2C+Emanuele&rft.au=Brown%2C+James&rft.au=Brunetti%2C+Enrico&rft.date=2016-11-01&rft.eissn=1399-3003&rft.volume=48&rft.issue=5&rft.spage=1411&rft_id=info:doi/10.1183%2F13993003.00510-2016&rft_id=info%3Apmid%2F27390280&rft.externalDocID=27390280 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0903-1936&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0903-1936&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0903-1936&client=summon |